AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
FLUTICASONE FUROATE
22 registrations across 7 African markets— 21 active
Markets with FLUTICASONE FUROATE
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| FURAMIST | 🇿🇦South Africa | Cipla Medpro (Pty) Ltd | active | Nov 2029 |
| AVAMYS NASAL SPRAY | 🇬🇭Ghana | SMITHKLINE BEECHAM LIMITED 980 GREAT WEST ROAD BRENTFORD MIDDLESEX TW 89GS | active | Jul 2029 |
| AVAMYS NASAL SPRAY | 🇬🇭Ghana | SMITHKLINE BEECHAM LIMITED 980 GREAT WEST ROAD BRENTFORD MIDDLESEX TW 89GS | active | Jul 2029 |
| ADVATIN NASAL SPRAY ( Fluticasone Furoate 0.05mg per actuation) | 🇬🇭Ghana | — | active | Feb 2029 |
| ADVATIN NASAL SPRAY ( Fluticasone Furoate 0.05mg per actuation) | 🇬🇭Ghana | — | active | Feb 2029 |
| Avamys Nasal Spray Suspension** Spray | 🇳🇬Nigeria | GlaxoSmithKline Consumer Nigeria PLC (GSK) | active | Jul 2028 |
| ELEBRATO ELLIPTA | 🇿🇦South Africa | GlaxoSmithKline South Africa (Pty) Limited | active | Jan 2026 |
| AVAMYS_NASAL 27.5mcg/SPRAY SPRAY SPRAY | 🇲🇼Malawi | — | expired | Mar 2025 |
| RELVAR ELIPTA 92/22 ug | 🇿🇦South Africa | GlaxoSmithKline South Africa (Pty) Limited | active | Jan 1900 |
| RELVAR ELIPTA 184/22 ug | 🇿🇦South Africa | GlaxoSmithKline South Africa (Pty) Limited | active | Jan 1900 |
| REVINTY ELIPTA 92/22 ug | 🇿🇦South Africa | GlaxoSmithKline South Africa (Pty) Limited | active | Jan 1900 |
| TRELEGY ELLIPTA | 🇿🇦South Africa | GlaxoSmithKline South Africa (Pty) Limited | active | Jan 1900 |
| GENEMIST | 🇿🇦South Africa | GlaxoSmithKline South Africa (Pty) Limited | active | Jan 1900 |
| AVAMYS | 🇿🇦South Africa | GlaxoSmithKline South Africa (Pty) Limited | active | Jan 1900 |
| REVINTY ELIPTA 184/22 ug | 🇿🇦South Africa | GlaxoSmithKline South Africa (Pty) Limited | active | Jan 1900 |
| FLUTICASONE
FUROATE NASAL TOPICAL
SPRAYS WITHOUT
GAS | 🇺🇬Uganda | GLAXOSMITHKLIN E LTD | active | — |
| FLUTICASONE
FUROATE NASAL TOPICAL
SPRAYS WITHOUT
GAS | 🇺🇬Uganda | GLAXOSMITHKLIN E LTD | active | — |
| FLUTICASONE
FUROATE NASAL TOPICAL
SPRAYS
WITHOUT GAS | 🇺🇬Uganda | GLAXOSMITHKLIN E LTD | active | — |
| NEOTISON® SUSP PPNAS BTE (1 FL X 120 DOSES) CELLCHEM suspension pour pulvérisation | 🇲🇬Madagascar | CELL CHEM PHARMACEUTICALS | active | — |
| AVA-MOX Nasal Spray | 🇹🇿Tanzania | Moriox Pharma Private Limited | active | — |
| NEOTISON® SUSP PPNAS BTE (1 FL X 120 DOSES) CELLCHEM suspension pour pulvérisation | 🇲🇬Madagascar | CELL CHEM PHARMACEUTICALS | active | — |
| FLUTICASONE
FUROATE NASAL TOPICAL
SPRAYS
WITHOUT GAS | 🇺🇬Uganda | GLAXOSMITHKLIN E LTD | active | — |
FLUTICASONE FUROATE in Africa — Regulatory Overview
FLUTICASONE FUROATE is registered across 7 African markets with 22 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including South Africa, Uganda, Ghana, Madagascar and 3 more. AfricaRegulatory refreshes this data daily from official government sources.
Of the 22 registrations, 21 (95%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.